Anirudh Yalamanchali

Anirudh Yalamanchali

Auto-generated profile, based on publicly available information

Anirudh Yalamanchali

Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JJJian-Yue Jin
Jian-Yue Jin
TMTodd Mereniuk
Todd Mereniuk
AYAnirudh Yalamanchali
Anirudh Yalamanchali
WWWeili Wang
Weili Wang
MMMitchell Machtay
Mitchell Machtay
SESusannah Ellsworth
Susannah Ellsworth

1 November 2019 in Radiation Research
Verified
Journal Article
Closed access
SESusannah G. Ellsworth
Susannah G. Ellsworth
AYAnirudh Yalamanchali
Anirudh Yalamanchali
HZHong Zhang
Hong Zhang
SGStuart A. Grossman
Stuart A. Grossman
RHRobert Hobbs
Robert Hobbs
JJJian-Yue Jin
Jian-Yue Jin
Radiation-induced lymphopenia (RIL) is associated with worse survival in patients with solid tumors, as well as lower response rates to checkpoint inhibitors. While single-fraction total-body irrad...

30 June 2014 in The Journal of Physical Chemistry A
Verified
Journal Article
Closed access
KPKatheryne L. Pyfer
Katheryne L. Pyfer
JKJared O. Kafader
Jared O. Kafader
AYAnirudh Yalamanchali
Anirudh Yalamanchali
MJMartin F. Jarrold
Martin F. Jarrold

2 May 2017 in The Journal of Physical Chemistry C
Verified
Journal Article
Closed access
AYAnirudh Yalamanchali
Anirudh Yalamanchali
KPKatheryne L. Pyfer
Katheryne L. Pyfer
MJMartin F. Jarrold
Martin F. Jarrold

1 January 2021 in Advances in Radiation Oncology
Verified
Journal Article
Open access
AYAnirudh Yalamanchali
Anirudh Yalamanchali
HZHong Zhang
Hong Zhang
KHKe Colin Huang
Ke Colin Huang
RMRadhe Mohan
Radhe Mohan
SLSteven H. Lin
Steven H. Lin
SESusannah G. Ellsworth
Susannah G. Ellsworth
Radiation therapy (RT)–induced lymphopenia (RIL) is linked with inferior survival in esophageal and pancreatic cancers. Previous work has demonstrated a correlation between spleen dose and RIL risk. The present study correlates spleen dose-volume parameters with fractional lymphocyte loss rate (FLL) and total percent change in absolute lymphocyte count (%ΔALC) and suggests spleen dose constraints to reduce RIL risk. This registry-based study included 140 patients who underwent RT for pancreatic (n = 67), gastroesophageal (n = 61), or biliary tract (n = 12) adenocarcinoma. Patient-specific parameters of lymphocyte loss kinetics, including FLL and %ΔALC, were calculated based on serial ALCs obtained during RT. Spearman’s rho was used to correlate spleen dose-volume parameters with %ΔALC, end-treatment ALC, and FLL. Multivariable logistic regression was used to identify predictors of ≥grade 3 and grade 4 RIL. Spleen dose-volume parameters, including mean spleen dose (MSD), all correlated with %ΔALC, end-treatment ALC, and FLL. Controlling for baseline ALC and planning target volume (PTV), an increase in any spleen dose-volume parameter increased the odds of developing ≥grade 3 lymphopenia. Each 1-Gy increase in MSD increased the odds of ≥grade 3 RIL by 18.6%, and each 100-cm3 increase in PTV increased the odds of ≥grade 3 lymphopenia by 20%. Patients with baseline ALC < 1500 cells/μL had a high risk of ≥grade 3 RIL regardless of MSD or PTV. FLL was an equally good predictor of ≥grade 3 lymphopenia as any spleen dose-volume parameter. In patients undergoing RT for upper abdominal malignancies, higher spleen dose is associated with higher per-fraction lymphocyte loss rates, higher total %ΔALC, and increased odds of severe lymphopenia. Spleen dose constraints should be individualized based on baseline ALC and PTV size to minimize RIL risk, although our findings require validation in larger, ideally prospective data sets.

20 February 2023 in Head & Neck
Verified
Journal Article
Open access
AYAnirudh Yalamanchali
Anirudh Yalamanchali
KYKailin Yang
Kailin Yang
LRLogan Roof
Logan Roof
NLNerea Lopetegui‐Lia
Nerea Lopetegui‐Lia
LSLarisa M. Schwartzman
Larisa M. Schwartzman
EYEmrullah Yilmaz
Emrullah Yilmaz
Objectives: Evaluate outcomes of patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy (IO).Methods: Among patients with R/M HNSCC treated with IO in this retrospective single‐institution cohort, Cox regression was used to compare overall survival (OS) for those with platinum‐refractory disease and those treated in the first‐line setting with OS from KEYNOTE‐040/048, respectively. Multivariable Cox regression was used to identify predictors of OS.Results: There was no significant OS difference for those treated in the platinum‐refractory setting when compared to patients on KEYNOTE‐040 (HR = 1.22, p = 0.27), nor for the first‐line setting compared to KEYNOTE‐048 (HR = 1.23, p = 0.19). ECOG‐PS 1 (HR = 2.00, p = 0.02) and ECOG‐PS 2 (HR = 3.13, p < 0.01) were associated with worse OS. Higher absolute lymphocyte count (ALC) was associated with improved OS (HR = 0.93 per 100 cells/μL, p = 0.03).Conclusions: Real‐world outcomes of IO in R/M HNSCC are similar to outcomes in randomized control trials, with performance status and ALC correlating with OS.